Literature DB >> 7027940

Stereotactic aspiration of deep cerebral abscesses after CT-directed labeling.

P R Walsh, S J Larson, M W Rytel, D J Maiman.   

Abstract

Multiple, deep cerebral abscesses were treated in 2 patients by stereotactic aspiration after CT-guided needle labeling of single cavities. Separation of labeling from stereotactic manipulations avoids CT artifact generated by standard frame components; the technique will, therefore, accommodate most stereotactic instruments in current use. Alignment of CT and stereotactic coordinates hinged upon coidentification of the Pantopaque-labeled cavity on CT scans and on routine skull films with the stereotactic frame in place. Proximity of the label to targets eliminated the need for special head fixation or complex baseline correction.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7027940     DOI: 10.1159/000102258

Source DB:  PubMed          Journal:  Appl Neurophysiol


  5 in total

1.  Applications of CT-adapted stereotaxis for the diagnosis and treatment of intracranial lesions.

Authors:  R D Lobato; J J Rivas
Journal:  Acta Neurochir (Wien)       Date:  1987       Impact factor: 2.216

2.  CT-guided stereotactic aspiration and treatment of brain abscesses. An experience with 24 cases.

Authors:  M G Hasdemir; U Ebeling
Journal:  Acta Neurochir (Wien)       Date:  1993       Impact factor: 2.216

Review 3.  Diagnosis and management of abscesses in the basal ganglia and thalamus: a survey.

Authors:  T W Lutz; H Landolt; M Wasner; O Gratzl
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

4.  Treatment of deep brain abscesses by stereotactic implantation of an intracavitary device for evacuation and local application of antibiotics.

Authors:  G Broggi; A Franzini; D Peluchetti; D Servello
Journal:  Acta Neurochir (Wien)       Date:  1985       Impact factor: 2.216

5.  Stereotactic aspiration of brain abscesses: is this the treatment of choice?

Authors:  S R Stapleton; B A Bell; D Uttley
Journal:  Acta Neurochir (Wien)       Date:  1993       Impact factor: 2.216

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.